ARMADA: Assessing reliable measurement in Alzheimer’s disease and cognitive aging project methods
| Autor: | Fatima Eldes, Richard Gershon, Felicia C. Goldstein, Hiroko H. Dodge, Dorene M. Rentz, Jennifer J. Manly, John A. Lucas, Jerry Slotkin, Emily Rogalski, Sandra Weintraub, David P. Salmon, Emily H. Ho, Vitali Ustsinovich, Bruno Giordani, John Devin Peipert, Katy Wortman, Tatiana Karpouzian-Rogers, Beth E. Snitz, Cynthia M. Carlsson, Michaela Riley, Cindy J. Nowinski |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Gerontology
Aging Longitudinal study Epidemiology Population Disease NIH Toolbox Neuropsychological Tests Cellular and Molecular Neuroscience Developmental Neuroscience Alzheimer Disease medicine Humans Dementia Cognitive Dysfunction Longitudinal Studies Cognitive decline education Aged Aged 80 and over education.field_of_study business.industry Health Policy Neuropsychology Cognition medicine.disease Psychiatry and Mental health Cognitive Aging Neurology (clinical) Geriatrics and Gerontology business |
| Zdroj: | Alzheimer's & Dementia. 18:1449-1460 |
| ISSN: | 1552-5279 1552-5260 |
| DOI: | 10.1002/alz.12497 |
| Popis: | Introduction Early detection of cognitive decline in older adults is a public health priority. Advancing Reliable Measurement in Alzheimer's Disease and Cognitive Aging (ARMADA), a multisite study, is validating cognition, emotion, motor, and sensory modules of the National Institutes of Health Toolbox for Assessment of Neurological and Behavioral Function (NIHTB) in the aging spectrum from cognitively normal to dementia of the Alzheimer's type (DAT). Methods Participants 65 to 85 years old, in demographic groups racially proportional to the general US population, are recruited in one of three groups to validate the NIHTB: cognitively normal, amnestic mild cognitive impairment (aMCI), or mild DAT. Additional special emphasis cohorts include (1) Blacks in the three clinical groups; (2) Spanish-speakers in the three clinical groups; (3) cognitively normal, population-proportional, over age 85. Discussion Longitudinal study will determine whether NIHTB can predict cognitive decline and is associated with Alzheimer's disease biomarkers. Here, we detail the methods for the ARMADA study. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|